1) Surgical candidates on CT should have a PET scan with
18-fluorodeoxyglucose (FDG) to look for involved intrathoracic nodes and distant metastases. 2) Patients who are otherwise surgical candidates and have limited N2/3 disease of uncertain pathological significance should also have an FDG-PET scan. 3) Histological/cytological investigation should be performed to confirm N2/3 disease when FDG-PET is positive. 4) Histological/cytological confirmation is not required when there is definite distant metastatic disease or a high probability that the N2/N3 disease is metastatic. 5) Biopsy is not required when an FDG-PET scan for N2/N3 disease is negative, even with enlarged nodes on CT.
The practice in our unit varies somewhat from these guidelines, thus we looked at the evidence behind some of these guidelines and developed a protocol for the use of PET and PET/CT based on the current literature.
The first point we looked at was the use of PET scanning in the evaluation of solitary pulmonary nodules (SPNs), as we felt that PET may be unnecessary for peripheral SPNs. Solitary pulmonary nodules are a common problem seen on up to 0.2% of chest radiographs. The prevalence of malignancy in SPNs has a large range, reported as 10%-68%, depending on the definition used (1-6 cm), selection criteria, and prevalence in the population. 3 A meta-analysis of 40 studies by Gould and colleagues 4 demonstrated PET sensitivity and specificity for malignancy of approximately 96.8% and 77.8%, respectively. They explained how these data need to be interpreted in the light of the pre-test probability of malignancy: "if we assume that the pretest probability of malignancy is 20% for a hypothetical low-risk patient with a pulmonary nodule, the post-test probability is about 1% when the FDG-PET result is negative. In contrast, for a high-risk patient (e.g., pre-test probability = 80%) with negative findings on FDG-PET, the post-test probability of malignancy is 14%. Thus, the negative predictive value depends on the pre-test probability of disease." Therefore, in patients with a high pre-test probability of malignancy (e.g., heavy smokers with a spiculated mass on CT), a negative PET may still leave a relatively high post-test probability of malignancy. In view of this, it is appropriate to offer such patients surgery even after a negative PET scan.
A second concern regarding the use of PET in SPN imaging is the ability to accurately show activity in small nodules. Current PET scanners have a spatial resolution in the order of 5-8 mm, therefore, they may miss lesions below 1 cm in size. Certain malignancies, such as bronchoalveolar carcinomas, adenocarcinoma, or carcinoid tumors may show little or no activity on PET scanning, giving a false-negative result. 5 A relatively small Japanese study comprising 57 patients looked at the role of video-assisted thoracoscopic surgery for diagnosis SPNs. 6 It concluded that videoassisted thoracoscopic excision of SPNs was safe, with sensitivity and specificity of almost 100%; all 57 patients obtained a histological diagnosis, with 57% being malignant. In light of this evidence, our current policy on SPNs is that for a peripheral nodule < 3 cm in a patient fit for surgery, excisional biopsy (preferably by video-assisted thoracoscopic surgery) is the procedure of choice. In patients who have comorbidities making them high risk for surgery, PET and interval CT may be useful. 7 This suggests that such patients should have histological staging prior to thoracotomy, to prevent unnecessary thoracotomies in this subgroup.
EDITORIAL
Lastly we looked at the evidence regarding PET vs PET/CT. PET/CT offers the advantage of giving both metabolic and anatomical information. Currently, there are few comparative trials of PET/CT vs PET. PET/CT is especially useful in patients with advanced tumors and extrathoracic disease. One study concluded that PET/CT was significantly more accurate for T staging of NSCLC compared to CT or PET alone, and that all modalities tended to under-stage the tumor; however, equivocal findings were reduced by PET/CT. 8 There is some evidence that PET/CT increases the number of patients needing invasive staging compared to PET alone. 9 This is explained by the fact that although integrated PET/CT has increased sensitivity (61.1% vs 85.7%) compared to PET, specificity is decreased (94.3% vs 80.6%). This gives fewer false negatives but an increase in false positives, as all false positives then require histological diagnosis, this increases the need for invasive staging. There are some concerns about PET/CT missing small nodules that would be seen on breath-hold CT alone, due to the fact that PET/CT is acquired during shallow breathing and lesions can be missed due to respiratory motion. Currently this is not a real problem as CT is much more available than PET/CT, meaning that almost all patients have had thorax CT prior to PET/CT. However, as PET/ CT becomes more available and cheaper, this may be a concern if used instead of breath-hold CT. 10 In conclusion, PET and PET/CT are increasingly useful investigations in the evaluation and staging of lung lesions. They allow us to stage patients more accurately and select the most appropriate candidates for surgery. Nevertheless, any clinician involved in using these imaging techniques must be aware of their strengths and weaknesses. Our current policy, based on the literature, is that all patients who are candidates for surgery or radical radiotherapy should undergo PET, except those with small (< 3 cm) peripheral SPNs. We suggest excisional biopsy for such lesions. PET and PET/CT are useful for evaluating mediastinal disease and metastatic spread, they are most useful for picking up patients with advanced-stage disease or extrathoracic spread. Most reports agree that PET-positive mediastinal nodes require histological confirmation, but in contrast to some guidelines, it appears that a negative PET result for mediastinal lymphadenopathy may still need further evaluation prior to thoracotomy.
